The aim of this study was to assess safety and efficacy of islet transplantation after initial pancreas transplantation with subsequent organ failure. Patients undergoing islet transplantation at our institution after pancreas organ failure were compared to a control group of patients with pancreas graft failure, but without islet transplantation and to a group receiving pancreas retransplantation. Ten patients underwent islet transplantation after initial pancreas transplantation failed and were followed for a median of 51 months. The primary end point of HbA1c <7.0% and freedom of severe hypoglycemia was met by nine of 10 patients after follow-up after islet transplantation and in all three patients in the pancreas retransplantation group, but by none of the patients in the group without retransplantation (n = 7). Insulin requirement was reduced by 50% after islet transplantation. Kidney function (eGFR) declined with a rate of -1.0 mL ± 1.2 mL/min/1.73 m 2 per year during follow-up after islet transplantation, which tended to be slower than in the group without retransplantation (P = .07). Islet transplantation after deceased donor pancreas transplant failure is a method that can safely improve glycemic control and reduce the incidence of severe hypoglycemia and thus establish similar glycemic control as after initial pancreas transplantation, despite the need of additional exogenous insulin.
| INTRODUCTION
Whole organ pancreas transplantation has been performed in patients with type 1 diabetes mellitus to restore glycemic control for 50 years. 1 Initially, long-lasting insulin independence was often not achieved. However, nowadays insulin independence is routinely achieved in the majority of patients after pancreas transplantation and is still present in 60%-70% of patients 5 years after transplantation. 2 In patients with loss of function of the transplanted pancreas, the question remains whether pancreas retransplantation should be recommended, in particular in patients after combined pancreas-kidney transplantation with a functioning kidney graft and continued immunosuppression. In most patients, glycemic control worsens again after pancreas failure despite optimal medical care (intensive insulin treatment). However, there are also factors that may prohibit whole organ retransplantation, because patients are older than at the time of the first transplantation and may suffer from additional cardiovascular complications that increase the risk of retransplantation. In addition, retransplantation may be technically more difficult in patients after previous abdominal surgery and with more advanced vascular disease. Pancreas transplantation, in contrast to kidney transplantation, is an intervention with a high complication rate. The reported rate of relaparotomy due to complications at the site of pancreas transplantation is about 30%-40% of patients. 3 Islet transplantation is an alternative to whole organ transplantation. This modality of transplantation was implemented by many centers mainly after the results of consistent insulin independence using a steroid-free immunosuppression protocol were published in 2000. 4 While insulin independence is generally achieved in a lower number of cases after islet transplantation 5 as compared to pancreas transplantation in most centers, good glycemic control comparable to whole organ transplantation can be routinely achieved with a much lower rate of complications. 6, 7 In addition, the results of islet transplantation have considerably improved in recent years. 8, 9 Thus, islet transplantation after initial pancreas transplantation and pancreas organ failure may be considered as an alternative to retransplantation of the whole organ.
The aim of this study was to evaluate the safety and efficacy (HbA1c <7.0% and freedom of severe hypoglycemia) of islet transplantation after donor pancreas failure in pancreas transplantation.
| PATIENTS AND METHODS

| Study design
All patients who underwent islet transplantation alone (ITA) or simultaneous islet-kidney transplantation (SIK) at the University Hospital Zurich between 1 January 2000 and 31 December 2015 after initial pancreas transplantation with pancreas organ failure were included in the study, as well as seven patients with pancreas organ failure but no consecutive retransplantation and three patients who received pancreas retransplantation as a control group. The possibility of pancreasor islet retransplantation was discussed with patients suffering from pancreas donor organ failure after initial transplantation at our institution. The decision regarding possible pancreas or islet retransplantation was made after considering the patient's preference as well as age and comorbidity.
Data of follow-up after islet transplantation were collected prospectively; data of follow-up after pancreas transplantation were collected prospectively after 2000 and retrospectively for patients who received a pancreas graft before 2000.
The primary end point was the achievement of HbA1c < 7.0% and freedom from severe hypoglycemic events as suggested by our group in 2008 10 and used in the CIT trials. 
| Patient selection for transplantation
Patient selection for islet after pancreas transplantation (vs pancreas retransplantation or best medical care) was performed after careful evaluation of possible advantages and disadvantages, with special regard to age and comorbidities. Patients considered being at higher risk for intra-operative complications were preferentially assigned to the less invasive procedure of islet transplantation, while only younger and healthier patients were offered both modalities (islet transplantation or pancreas retransplantation).
| Assessment of diabetes-related complications and cardiovascular risk factors
Retinopathy was defined according to the diagnosis made by ophthalmological examination. Peripheral neuropathy was defined by clinical examination, using the Michigan Neuropathy Screening Instrument (MNSI), 11 monofilament pressure sensation, and electrodiagnostic testing in atypical cases. Autonomic neuropathy was diagnosed by the history and clinical examination, which included computer analysis of heart rate variability (ProSciCard, CPS GmbH, Wetzlar, Germany).
Macrovascular disease was assessed by patient history, physical examination, and angiography results.
Severe hypoglycemia was defined as any hypoglycemic event that required assistance from another person to treat or loss of consciousness. Preparation and transplantation of the pancreatic islets were performed as described previously. 13 Transplanted islets were not cultured before transplantation. Islet transplantation was conducted by a transhepatic percutaneous approach. Islet volume is given as islet equivalents (IEQ) 14 and islet number.
| Biochemical analyses
Pancreas organ failure was defined as C-peptide (stimulated) of less than 100 pmol/L, and/or HbA1c >8%.
| Immunosuppression
Immunosuppression after initial pancreas transplantation included a regimen with tacrolimus 15 and mycophenolate mofetil, 16 as well as prednisone. Induction therapy was performed initially with basiliximab, later with thymoglobulin. 17 Target trough levels for tacrolimus persisted, and/or in case of recurrent severe hypoglycemia after islet transplantation, the possibility of an additional islet transplantation was offered to the patient. 
| Statistical analysis
| RESULTS
| Patient and transplant characteristics
A total of 10 patients received islet transplantation after organ function failure of the transplanted pancreas after SPK transplantation (group 1). For comparison, seven patients with pancreas failure after SPK transplantation, but without retransplantation, were included in the analysis (group 2). Further data of a smaller group (n = 3, group 3)
of patients with pancreas retransplantation were also included in the analysis.
Time between pancreas transplantation and pancreas organ failure was 2 months in group 1 (median; range: 0-6.9 years), 11 months in group 2 (range: 0-5.9 years; ns), and 2 months in group 3 (range: 0-0.8 years; ns). Two patients in group 1 and 2, and one patient in group 3 lost the organ within the first month after transplantation. The reasons for pancreas organ loss in the three groups were acute rejection (1 patient in group 1 and 2), chronic rejection (4, 2, and 1 patient in the 3 groups, respectively), and vascular causes (5, 4, and 1 patient).
Baseline characteristics of patients are described in Table 1 .
Duration between pancreas and islet transplantation was 6.1 years (median, range: 1.9-29.4 years), between pancreas and pancreas retransplantation 1.1 years (0.5-7.7 years). At the time of islet transplantation, 9 of 10 patients presented with an HbA1c > 7.0% (3 of 3 patients in the pancreas retransplantation group), and the occurrence of severe hypoglycemia was registered in seven patients (2 in the pancreas retransplantation group).
Transplant characteristics including number of islet infusions, transplanted islet number, and volume (IEQ/kg body weight) are also shown in Table 1 . The mean number of transplantations was 1.6 ± 1.3
per patient.
The 16 islet donors had a mean age of 56.8 ± 10.1 years, and the three pancreas (retransplantation) donors had an age of 38.9 ± 5.1 years (P < .01). Donor age of the initial pancreas transplantation was 36.1 ± 12.7 years in group 1, 27.0 ± 11.3 years in group 2, and 42.3 ± 9.0 years in group 3, ns; 52.6% of islet donors were fe- 
| Diabetes-related and macrovascular complications, hypertension, smoking
Proliferative retinopathy was present in 80%, 100%, and 100% of patients at baseline in groups 1, 2, and 3, respectively (ns). All patients suffered from end-stage renal disease. Peripheral and/or autonomic neuropathy were present in 90%, 100%, and 100% of patients in the three groups (ns); 70%, 70%, and 67% in the three groups suffered from cardiovascular disease (ns); and 70%, 100%, and 67% had arterial hypertension (ns). Two patients in group 2 were smokers.
| Glycemic control and incidence of hypoglycemia
The primary end point of HbA1c < 7.0% and freedom of severe hypoglycemia was successfully met by all patients after islet transplantation at 1 year and 90% at the end of follow-up (group 1), but by none of the patients without retransplantation (group 2) (P < .001). In group 3 (pancreas retransplantation), the primary end point was met by all patients after retransplantation and at the end of follow-up.
Glycated hemoglobin (HbA1c) decreased after pancreas transplantation by 2.5% from baseline (8.5 ± 1.8%) to 6.0 ± 0.3% in group 1, by 2.0% from baseline (7.8 ± 1.1%) to 5.8 ± 0.9% in group 2 (P < .05 for both), and by 2.6% from baseline (7.7 ± 1.7%) to 5.1 ± 0.4% in group 3 (ns). However, it increased again after pancreas transplant failure. After In group 3, all patients became insulin-independent after pancreas retransplantation, and insulin independency was preserved until the end of follow-up (with a mean HbA1c of < 6% during follow-up as described above; HbA1c 1 year after transplantation: 5.7 ± 0.4%).
The frequency of severe hypoglycemia decreased from 120 to 5
per 100 patient years after islet transplantation (occurring in 1 patient with negative C-peptide) (P = .03) and from 70 to 0 per 100 patient years after pancreas retransplantation.
| Cardiovascular risk factors and kidney function during follow-up
Weight, kidney function, blood pressure, and serum lipid levels are shown in Table 2 . Significant changes observed after islet transplantation were reductions of LDL cholesterol (end of follow-up) and of triglyceride levels (initially after transplantation). Age at islet (pancreas re) transplantation (y) 52.2 ± 6.0 n/a 38.4 ± 6.7 .03
Number of islet transplantations (n) 1.6 ± 1.3 n/a n/a Total islet number per kg body weight (n) 9405 ± 9547 n/a n/a Total islet equivalent per kg body weight (IEQ) 9676 ± 9785 n/a n/a Data are given as mean ± SD or %. Group 1: patients with islet transplantation after pancreas organ failure, group 2: patients with pancreas failure but without retransplantation, group 3: patients with pancreas failure and pancreas retransplantation. P: P-value for statistical difference between the three groups.
T A B L E 1 Patient and transplantation characteristics
Kidney function in terms of eGFR declined with a rate of 
| Side effects of islet transplantation
There was no need for surgical intervention after any of the islet infusion procedures. All patients received immunosuppression primarily for the transplanted kidney, and there were no short-term side effects that could be attributed to the change in immunosuppression (induction therapy).
In one of three patients after pancreas retransplantation, revision surgery (relaparotomy) due to hematoma had to be performed.
| DISCUSSION
Our study evaluated the effect of islet transplantation in a cohort of patients with failed pancreas organ function after combined pancreaskidney transplantation with a long-term follow-up of more than 4 years. This cohort was compared to a second cohort receiving no retransplantation after pancreas organ failure and to three patients receiving pancreas retransplantation after failure of function of the initially transplanted pancreas.
Studies on the outcome of pancreas retransplantation after fail- 
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F I G U R E 1 Median HbA1c (%, 1./3. Quartile, range) before and after pancreas transplantation, after pancreas failure and during follow-up after retransplantation in patients with (group 1, bright gray bars) and without consecutive islet transplantation (group 2, white bars), as well as in patients with pancreas retransplantation (group 3, dark gray bars). PTPL, pancreas transplantation; ITPL, islet transplantation; PRTPL, pancreas retransplantation. *Significantly different from baseline, P < .05. †
Significant difference between groups, P < .01 F I G U R E 2 Median C-peptide levels (A) and insulin requirement (B) (1./3. Quartile, range) before and after islet transplantation (ITPL). *Different from baseline, P < .05 78 ± 4* ITPL, islet transplantation; PRTPL, pancreas retransplantation; PTPL, pancreas transplantation. *Significant difference between groups (P < .05). **Significantly different compared with levels before pancreas transplantation (P < .05). ***Significantly different compared with levels before islet (or pancreas re-) transplantation (P < .05).
As patient mortality and technical failure were not increased after pancreas retransplantation in the large Minnesota cohort, pancreas retransplantation can be considered a procedure as safe as the first transplantation. 23 However, it is important to point out that the mean recipient age in this cohort was less than 45 years. Higher patient age, with an increased disease burden and frequency of cardiovascular morbidity and vascular disease, may increase technical problems as well as the complication risk in pancreas retransplantation. Thus, it is presently not known, whether pancreas retransplantation can be considered to be safe also in older recipients like the ones evaluated in our study, with a mean age of more than 52 years.
As demonstrated here, islet transplantation after failed pancreas transplantation was a safe procedure in these 10 older patients, with a diabetes duration of more than 40 years at transplantation and established cardiovascular disease in seven of 10 patients.
Importantly, with a mean of 1.6 islet transplantations per recipient, it was possible to lower HbA1c to levels similar to those after initial pancreas transplantation (and similar to those after pancreas retransplantation in the third group) and to reduce the incidence of severe hypoglycemia by more than 20-fold to a rate that was much lower than the one reported for patients receiving intensive or even less intensive insulin treatment in the DCCT 25 or in our own cohort, 26 where HbA1c levels were substantially higher than in patients after islet transplantation as described here. This improvement was observed despite a need for some exogenous insulin in all patients at the end of follow-up. Thus, we conclude that even low levels of endogenous insulin as observed in our cohort (positive C-peptide response in 9 of 10 patients) are sufficient to support exogenous insulin therapy to facilitate glucose control and prevent severe hypoglycemia by more than 95%, obtaining similar results as compared to whole organ pancreas transplantation. The insulin requirement was 38% less than before transplantation at the end of follow-up. Of course, islet transplantation has to be seen as part of a multimodality approach, and optimal support regarding insulin therapy is necessary to achieve good glycemic control. On the other hand, even optimal conservative therapy (as provided to the group without retransplantation) was not sufficient to achieve good glycemic control when not supported by a certain amount of endogenous insulin production.
The primary end point of good glycemic control (HbA1c < 7%) and avoidance of severe hypoglycemia 1 year after transplantation was achieved in a high proportion of patients (90%) that was similar to the primary outcome of the recently published trial of the CIT Consortium (88% of patients), 9 with a slightly lower number of IEQ transplanted per kg patient weight in our study. In contrast, it was not possible to achieve HbA1c levels below 7% in any patient in the control group without islet transplantation after pancreas failure. The insulin dosage that was necessary after transplantation was higher in our study compared to the CIT trial. Besides the lower amount of transplanted IEQ, this might also be due to a higher proportion of sensitization in patients after pancreas transplantation (in particular with some patients who lost function of the organ due to rejection) and thus a higher amount of loss of transplanted islets by rejection.
When compared to the earlier published results of the whole cohort of patients receiving islet transplantation at our center, 7 glycemic control was slightly better in patients described here with islet after pancreas transplantation (HbA1c of 6.2% vs 6.5%). The two patients with PRA levels >0% showed a tendency toward a somewhat higher HbA1c at the end of follow-up (6.6% vs 6.1%), but the low number of these patients prohibits any conclusions. Further comparison of HbA1c levels that were achieved in our cohort after islet transplantation with those of patients receiving pancreas retransplantation in cohorts from other centers reveals only slightly higher HbA1c values (HbA1c of around 6% during follow-up, compared with levels around 5.5% described in 22 ).
Further, a good glucose control could be achieved despite a relatively high donor age (compared to the whole organ donors). The older donor age is mainly due to the allocation criteria in Switzerland, where organs of younger donors are preferentially used for whole organ transplantation.
It was previously shown that islet transplantation may slow down the progression of nephropathy 27 and neuropathy. 28 In light of the high rate of already established diabetes complications at baseline, we did not evaluate the progression of complications in this study, with the exception of renal function of the transplanted kidney. We observed a decline in eGFR of -1.0 mL/min/1.73 m 2 per year, which is similar to the rate that is observed in pancreas transplantation at our institution 7 as well as by other groups. 29 In the group without islet transplantation, eGFR decline was higher (albeit not statistically significant). Body weight and cardiovascular risk factors as blood pressure and serum lipids remained stable after islet transplantation.
Although the small number of islet recipients studied represents a clear limitation, we believe that it is of importance to address the issue of retransplantation for this very specific population (pancreas organ failure and retransplantation at relatively high age, with high perioperative cardiovascular risk due to coronary heart disease), which we believe to be small in most centers performing pancreas and islet transplantation. Even if the follow-up time of 4 years might be considered relatively short, we have individual observation times of up to 12 years and a long duration after kidney transplantation, which is likely to be sufficient to demonstrate safety and efficacy of islet transplantation after pancreas organ failure. Nonetheless, it has to be mentioned that some possible side effects, for example, long-term effects of induction therapy, could not be assessed within the follow-up of our study as this would need a longer observation time.
A recent publication reported results of islet after combined or sequential pancreas-kidney transplantation (as well as pancreas after islet transplantation). 30 However, this study included only three transplanted patients with a younger mean age (39.7 years). There was only one older patient (52 years), and this patient showed persistent high blood glucose levels after islet transplantation (HbA1c 12.1% at the end of follow-up). Thus, we believe that our study extends the current knowledge with important information regarding the safety and efficacy of islet after pancreas transplantation also in a cohort of older patients.
In summary, we were able to demonstrate in this study that islet transplantation after failed initial pancreas transplantation is a method that can safely improve glycemic control (HbA1c < 7%) and reduce the incidence of severe hypoglycemia. It is able to establish comparable glycemic control as after initial pancreas transplantation (despite the need of additional exogenous insulin after islet transplantation) and to protect the transplanted kidney from re-occurrence of diabetic nephropathy.
